Cargando…

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities

Detalles Bibliográficos
Autores principales: Nichols, Dave P., Durmowicz, Anthony G., Field, Ann, Flume, Patrick A., VanDevanter, Donald R., Mayer-Hamblett, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491060/
https://www.ncbi.nlm.nih.gov/pubmed/30658043
http://dx.doi.org/10.1513/AnnalsATS.201812-863OT
_version_ 1783414915399155712
author Nichols, Dave P.
Durmowicz, Anthony G.
Field, Ann
Flume, Patrick A.
VanDevanter, Donald R.
Mayer-Hamblett, Nicole
author_facet Nichols, Dave P.
Durmowicz, Anthony G.
Field, Ann
Flume, Patrick A.
VanDevanter, Donald R.
Mayer-Hamblett, Nicole
author_sort Nichols, Dave P.
collection PubMed
description
format Online
Article
Text
id pubmed-6491060
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Thoracic Society
record_format MEDLINE/PubMed
spelling pubmed-64910602019-05-10 Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities Nichols, Dave P. Durmowicz, Anthony G. Field, Ann Flume, Patrick A. VanDevanter, Donald R. Mayer-Hamblett, Nicole Ann Am Thorac Soc Perspective American Thoracic Society 2019-05 /pmc/articles/PMC6491060/ /pubmed/30658043 http://dx.doi.org/10.1513/AnnalsATS.201812-863OT Text en Copyright © 2019 by the American Thoracic Society http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).
spellingShingle Perspective
Nichols, Dave P.
Durmowicz, Anthony G.
Field, Ann
Flume, Patrick A.
VanDevanter, Donald R.
Mayer-Hamblett, Nicole
Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
title Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
title_full Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
title_fullStr Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
title_full_unstemmed Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
title_short Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
title_sort developing inhaled antibiotics in cystic fibrosis: current challenges and opportunities
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491060/
https://www.ncbi.nlm.nih.gov/pubmed/30658043
http://dx.doi.org/10.1513/AnnalsATS.201812-863OT
work_keys_str_mv AT nicholsdavep developinginhaledantibioticsincysticfibrosiscurrentchallengesandopportunities
AT durmowiczanthonyg developinginhaledantibioticsincysticfibrosiscurrentchallengesandopportunities
AT fieldann developinginhaledantibioticsincysticfibrosiscurrentchallengesandopportunities
AT flumepatricka developinginhaledantibioticsincysticfibrosiscurrentchallengesandopportunities
AT vandevanterdonaldr developinginhaledantibioticsincysticfibrosiscurrentchallengesandopportunities
AT mayerhamblettnicole developinginhaledantibioticsincysticfibrosiscurrentchallengesandopportunities